WHO ICTRP trial
THE MOLECULAR MECHANISM AND REVERSE MULTI-DRUG RESISTANCE OF ELEMENE IN LUNG…
ChiCTR-IPR-17012912 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-IPR-17012912 |
|---|---|
| Public title | THE MOLECULAR MECHANISM AND REVERSE MULTI-DRUG RESISTANCE OF ELEMENE IN LUNG CANCER |
| Scientific title | THE MOLECULAR MECHANISM AND REVERSE MULTI-DRUG RESISTANCE OF ELEMENE IN LUNG CANCER |
| Primary sponsor | HI CANCER CENTER, AFFILATED HOSPITAL OF HANGZHOU NORMAL UNIVERSITY |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | Post-market |
| Countries | China |
| Conditions | LUNG CANCER |
| Interventions | CONTROL GROUP:EGFR TKI;STUDY GROUP:ELEMMENE+EGFR TKI |
| Registration date | Oct 9, 2017 |
| Target size | CONTROL GROUP:600;STUDY GROUP:600 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: